Details of the Drug

General Information of Drug (ID: DM1YBHK)

Drug Name
Rifabutin
Synonyms
Alfacid; Ansamycin; Ansatipin; Ansatipine; Assatipin; Mycobutin; RBT; Rifabutina; Rifabutine; Rifabutinum; Grunenthal Brand of Rifabutin; Kenfarma Brand of Rifabutin; Pfizer Brand of Rifabutin; Rifabutin Pfizer Brand; Rifabutina [Spanish]; Rifabutine [French]; Rifabutinum [Latin]; Antibiotic LM 427; LM 427; LM427; DRG-0085; LM-427; Mycobutin (TN); Rifabutin [USAN:BAN:INN]; Rifabutin (JAN/USP/INN); Mycobutin, Ansamycin, LM 427, Ansatipine, Rifabutin; (9S,12E,14S,15R,16S,17R,18R,19R,20S,21S,22E,24Z)-6,18,20-trihydroxy-1'-isobutyl-14-methoxy-7,9,15,17,19,21,25-heptamethyl-5,10,26-trioxo-3,5,9,10-tetrahydrospiro[9,4-(epoxypentadeca[1,11,13]trienoimino)furo[2',3':7,8]naphtho[1,2-d]imidazole-2,4'-piperidin; Spiro[9,4-(epoxypentadeca[1,11,13]trienimino)-2H-furo[2',3':7,8]naphth[1,2-d]imidazole-2,4'-piperidine]-5,10,26(3H,9H)-trione, 16-(acetyloxy)-6,18,20-trihydroxy-14-methoxy-7,9,15,17,19,21,25-heptameth; 1,4-Dihydro-1-deoxy-1',4-didehydro-5'-(2-methylpropyl)-1-oxorifamycin XIV; 4-Deoxo-3,4-(2-spiro(N-isobutyl-4-piperidyl)-2,5-dihydro-1H-imidazo)-rifamycin S; 4-N-isobutylspiropiperidylrifamycin S
Indication
Disease Entry ICD 11 Status REF
Mycobacterium infection 1B10-1B21 Approved [1]
Tuberculosis 1B10-1B14 Approved [1]
Therapeutic Class
Antibiotics
Drug Type
Small molecular drug
Structure
3D MOL is unavailable 2D MOL
#Ro5 Violations (Lipinski): 2 Molecular Weight (mw) 847
Topological Polar Surface Area (xlogp) 4.7
Rotatable Bond Count (rotbonds) 5
Hydrogen Bond Donor Count (hbonddonor) 5
Hydrogen Bond Acceptor Count (hbondacc) 14
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [2]
Bioavailability
The bioavailability of drug is 20% [3]
Clearance
The clearance of drug is 0.69 +/- 0.32 L/h/kg [4]
Elimination
10% of drug is excreted from urine in the unchanged form [2]
Half-life
The concentration or amount of drug in body reduced by one-half in 45 +/- 17 hours [5]
Metabolism
The drug is metabolized via the hepatic [3]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 5.0597 micromolar/kg/day [6]
Unbound Fraction
The unbound fraction of drug in plasma is 0.29% [5]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 9.3 L/kg [5]
Water Solubility
The ability of drug to dissolve in water is measured as 0.19 mg/mL [2]
Chemical Identifiers
Formula
C46H62N4O11
IUPAC Name
[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,32-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-1'-(2-methylpropyl)-6,23-dioxospiro[8,33-dioxa-24,27,29-triazapentacyclo[23.6.1.14,7.05,31.026,30]tritriaconta-1(32),2,4,9,19,21,24,26,30-nonaene-28,4'-piperidine]-13-yl] acetate
Canonical SMILES
C[C@H]1/C=C/C=C(\\C(=O)N=C2C(=C3C(=C4C2=NC5(N4)CCN(CC5)CC(C)C)C6=C(C(=C3O)C)O[C@@](C6=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)O)/C
InChI
InChI=1S/C46H62N4O11/c1-22(2)21-50-18-16-46(17-19-50)48-34-31-32-39(54)28(8)42-33(31)43(56)45(10,61-42)59-20-15-30(58-11)25(5)41(60-29(9)51)27(7)38(53)26(6)37(52)23(3)13-12-14-24(4)44(57)47-36(40(32)55)35(34)49-46/h12-15,20,22-23,25-27,30,37-38,41,48,52-55H,16-19,21H2,1-11H3/b13-12+,20-15+,24-14-,47-36?/t23-,25+,26+,27+,30-,37-,38+,41+,45-/m0/s1
InChIKey
ZWBTYMGEBZUQTK-PVLSIAFMSA-N
Cross-matching ID
PubChem CID
135398743
CAS Number
72559-06-9
DrugBank ID
DB00615
TTD ID
D05CHI
INTEDE ID
DR1418
ACDINA ID
D00590

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
DNA-directed RNA polymerase (RNAP) TTHKJLN NOUNIPROTAC Modulator [7]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [8]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Rifabutin (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Clindamycin DM15HL8 Moderate Increased metabolism of Rifabutin caused by Clindamycin mediated induction of CYP450 enzyme. Acne vulgaris [ED80] [20]
Repaglinide DM5SXUV Moderate Increased metabolism of Rifabutin caused by Repaglinide mediated induction of CYP450 enzyme. Acute diabete complication [5A2Y] [21]
Glibenclamide DM8JXPZ Moderate Increased metabolism of Rifabutin caused by Glibenclamide mediated induction of CYP450 enzyme. Acute diabete complication [5A2Y] [22]
Tolazamide DMIHRNA Moderate Increased metabolism of Rifabutin caused by Tolazamide mediated induction of CYP450 enzyme. Acute diabete complication [5A2Y] [22]
Pioglitazone DMKJ485 Moderate Increased metabolism of Rifabutin caused by Pioglitazone mediated induction of CYP450 enzyme. Acute diabete complication [5A2Y] [23]
Glipizide DMZA5PQ Moderate Increased metabolism of Rifabutin caused by Glipizide mediated induction of CYP450 enzyme. Acute diabete complication [5A2Y] [22]
Midostaurin DMI6E0R Moderate Increased metabolism of Rifabutin caused by Midostaurin mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [24]
Oliceridine DM6MDCF Major Increased metabolism of Rifabutin caused by Oliceridine mediated induction of CYP450 enzyme. Acute pain [MG31] [25]
Donepezil DMIYG7Z Moderate Increased metabolism of Rifabutin caused by Donepezil mediated induction of CYP450 enzyme. Alzheimer disease [8A20] [26]
Metronidazole DMTIVEN Moderate Increased metabolism of Rifabutin caused by Metronidazole mediated induction of CYP450 enzyme. Amoebiasis [1A36] [27]
Bepridil DM0RKS4 Major Increased metabolism of Rifabutin caused by Bepridil mediated induction of CYP450 enzyme. Angina pectoris [BA40] [28]
Dronedarone DMA8FS5 Moderate Increased metabolism of Rifabutin caused by Dronedarone mediated induction of CYP450 enzyme. Angina pectoris [BA40] [29]
Nifedipine DMSVOZT Major Increased metabolism of Rifabutin caused by Nifedipine mediated induction of CYP450 enzyme. Angina pectoris [BA40] [28]
Bedaquiline DM3906J Major Increased metabolism of Rifabutin caused by Bedaquiline mediated induction of CYP450 enzyme. Antimicrobial drug resistance [MG50-MG52] [30]
Clorazepate DMC3JST Minor Increased metabolism of Rifabutin caused by Clorazepate mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [31]
Posaconazole DMUL5EW Moderate Accelerated clearance of Rifabutin due to the transporter induction by Posaconazole. Aspergillosis [1F20] [30]
Tindamax DM3OWT4 Moderate Increased metabolism of Rifabutin caused by Tindamax mediated induction of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [27]
Clarithromycin DM4M1SG Moderate Increased metabolism of Rifabutin caused by Clarithromycin mediated induction of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [32]
Troleandomycin DMUZNIG Moderate Increased metabolism of Rifabutin caused by Troleandomycin mediated induction of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [32]
Telithromycin DMZ4P3A Major Increased metabolism of Rifabutin caused by Telithromycin mediated induction of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [30]
Cariprazine DMJYDVK Moderate Increased metabolism of Rifabutin caused by Cariprazine mediated induction of CYP450 enzyme. Bipolar disorder [6A60] [33]
Erdafitinib DMI782S Major Increased metabolism of Rifabutin caused by Erdafitinib mediated induction of CYP450 enzyme. Bladder cancer [2C94] [34]
Pexidartinib DMS2J0Z Major Decreased metabolism of Rifabutin caused by Pexidartinib mediated inhibition of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [35]
Ixabepilone DM2OZ3G Moderate Increased metabolism of Rifabutin caused by Ixabepilone mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [36]
Lapatinib DM3BH1Y Moderate Increased metabolism of Rifabutin caused by Lapatinib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [37]
HKI-272 DM6QOVN Major Increased metabolism of Rifabutin caused by HKI-272 mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [37]
LY2835219 DM93VBZ Moderate Increased metabolism of Rifabutin caused by LY2835219 mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [38]
Exemestane DM9HPW3 Moderate Increased metabolism of Rifabutin caused by Exemestane mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [39]
Esterified estrogens DM9KZDO Moderate Increased metabolism of Rifabutin caused by Esterified estrogens mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [40]
Tucatinib DMBESUA Major Increased metabolism of Rifabutin caused by Tucatinib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [41]
Palbociclib DMD7L94 Major Increased metabolism of Rifabutin caused by Palbociclib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [37]
Alpelisib DMEXMYK Major Increased metabolism of Rifabutin caused by Alpelisib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [42]
Quinestrol DMJ6H1Z Moderate Increased metabolism of Rifabutin caused by Quinestrol mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [40]
Tamoxifen DMLB0EZ Moderate Increased metabolism of Rifabutin caused by Tamoxifen mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [43]
Cabazitaxel DMPAZHC Moderate Increased metabolism of Rifabutin caused by Cabazitaxel mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [44]
Bosutinib DMTI8YE Major Increased metabolism of Rifabutin caused by Bosutinib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [45]
Estradiol DMUNTE3 Moderate Increased metabolism of Rifabutin caused by Estradiol mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [46]
Atorvastatin DMF28YC Moderate Increased metabolism of Rifabutin caused by Atorvastatin mediated induction of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [47]
Macitentan DMP79A1 Major Increased metabolism of Rifabutin caused by Macitentan mediated induction of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [48]
Doxercalciferol DM6FG1P Moderate Increased metabolism of Rifabutin caused by Doxercalciferol mediated induction of CYP450 enzyme. Chronic kidney disease [GB61] [49]
PF-04449913 DMSB068 Major Increased metabolism of Rifabutin caused by PF-04449913 mediated induction of CYP450 enzyme. Chronic myelomonocytic leukaemia [2A40] [50]
Dihydrocodeine DMB0FWL Moderate Increased metabolism of Rifabutin caused by Dihydrocodeine mediated induction of CYP450 enzyme. Chronic pain [MG30] [51]
Anisindione DM2C48U Major Increased metabolism of Rifabutin caused by Anisindione mediated induction of CYP450 enzyme. Coagulation defect [3B10] [52]
Regorafenib DMHSY1I Moderate Increased metabolism of Rifabutin caused by Regorafenib mediated induction of CYP450 enzyme. Colorectal cancer [2B91] [53]
Irinotecan DMP6SC2 Major Increased metabolism of Rifabutin caused by Irinotecan mediated induction of CYP450 enzyme. Colorectal cancer [2B91] [54]
Drospirenone DM1A9W3 Major Increased metabolism of Rifabutin caused by Drospirenone mediated induction of CYP450 enzyme. Contraceptive management [QA21] [55]
Levonorgestrel DM1DP7T Major Increased metabolism of Rifabutin caused by Levonorgestrel mediated induction of CYP450 enzyme. Contraceptive management [QA21] [55]
Ulipristal DMBNI20 Moderate Increased metabolism of Rifabutin caused by Ulipristal mediated induction of CYP450 enzyme. Contraceptive management [QA21] [30]
Norgestimate DMYP4XC Major Increased metabolism of Rifabutin caused by Norgestimate mediated induction of CYP450 enzyme. Contraceptive management [QA21] [56]
Levobupivacaine DM783CH Minor Increased metabolism of Rifabutin caused by Levobupivacaine mediated induction of CYP450 enzyme. Corneal disease [9A76-9A78] [57]
Halothane DM80OZ5 Major Increased risk of hepatotoxicity by the combination of Rifabutin and Halothane. Corneal disease [9A76-9A78] [58]
Alfentanil DMVO0UB Moderate Increased metabolism of Rifabutin caused by Alfentanil mediated induction of CYP450 enzyme. Corneal disease [9A76-9A78] [59]
Mifepristone DMGZQEF Moderate Increased metabolism of Rifabutin caused by Mifepristone mediated induction of CYP450 enzyme. Cushing syndrome [5A70] [60]
Osilodrostat DMIJC9X Major Increased metabolism of Rifabutin caused by Osilodrostat mediated induction of CYP450 enzyme. Cushing syndrome [5A70] [30]
Ivacaftor DMZC1HS Major Increased metabolism of Rifabutin caused by Ivacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [37]
MK-8228 DMOB58Q Moderate Accelerated clearance of Rifabutin due to the transporter induction by MK-8228. Cytomegaloviral disease [1D82] [37]
Rivaroxaban DMQMBZ1 Moderate Increased metabolism of Rifabutin caused by Rivaroxaban mediated induction of CYP450 enzyme. Deep vein thrombosis [BD71] [61]
Vilazodone DM4LECQ Moderate Increased metabolism of Rifabutin caused by Vilazodone mediated induction of CYP450 enzyme. Depression [6A70-6A7Z] [62]
Nefazodone DM4ZS8M Moderate Decreased metabolism of Rifabutin caused by Nefazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [63]
Vortioxetine DM6F1PU Moderate Increased metabolism of Rifabutin caused by Vortioxetine mediated induction of CYP450 enzyme. Depression [6A70-6A7Z] [64]
OPC-34712 DMHG57U Moderate Increased metabolism of Rifabutin caused by OPC-34712 mediated induction of CYP450 enzyme. Depression [6A70-6A7Z] [65]
Polatuzumab vedotin DMF6Y0L Minor Increased metabolism of Rifabutin caused by Polatuzumab vedotin mediated induction of CYP450 enzyme. Diffuse large B-cell lymphoma [2A81] [37]
[3H]estrone-3-sulphate DMGPF0N Moderate Increased metabolism of Rifabutin caused by [3H]estrone-3-sulphate mediated induction of CYP450 enzyme. Discovery agent [N.A.] [46]
Ospemifene DMC4GEI Moderate Increased metabolism of Rifabutin caused by Ospemifene mediated induction of CYP450 enzyme. Dyspareunia [GA12] [66]
Ingrezza DMVPLNC Major Increased metabolism of Rifabutin caused by Ingrezza mediated induction of CYP450 enzyme. Dystonic disorder [8A02] [67]
Oestradiol valerate and dienogest DMZK0FQ Major Increased metabolism of Rifabutin caused by Oestradiol valerate and dienogest mediated induction of CYP450 enzyme. Endometriosis [GA10] [56]
Diazepam DM08E9O Minor Increased metabolism of Rifabutin caused by Diazepam mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [31]
Zonisamide DM0DTF7 Moderate Increased metabolism of Rifabutin caused by Zonisamide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [68]
Felbamate DM1V5ZS Moderate Increased metabolism of Rifabutin caused by Felbamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [69]
Cenobamate DMGOVHA Moderate Increased metabolism of Rifabutin caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [70]
Stiripentol DMMSDOY Major Increased metabolism of Rifabutin caused by Stiripentol mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [30]
Fosphenytoin DMOX3LB Moderate Increased metabolism of Rifabutin caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [71]
Clonazepam DMTO13J Minor Increased metabolism of Rifabutin caused by Clonazepam mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [31]
Ethotoin DMXWOCP Moderate Increased metabolism of Rifabutin caused by Ethotoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [71]
Cannabidiol DM0659E Moderate Increased metabolism of Rifabutin caused by Cannabidiol mediated induction of CYP450 enzyme. Epileptic encephalopathy [8A62] [30]
Nicardipine DMCDYW7 Major Increased metabolism of Rifabutin caused by Nicardipine mediated induction of CYP450 enzyme. Essential hypertension [BA00] [28]
Praziquantel DMOU1PK Major Increased metabolism of Rifabutin caused by Praziquantel mediated induction of CYP450 enzyme. Flatworm infection [1F70-1F86] [72]
Bay 80-6946 DMLOS5R Moderate Accelerated clearance of Rifabutin due to the transporter induction by Bay 80-6946. Follicular lymphoma [2A80] [73]
Tazemetostat DMWP1BH Major Increased metabolism of Rifabutin caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [74]
Solifenacin DMG592Q Moderate Increased metabolism of Rifabutin caused by Solifenacin mediated induction of CYP450 enzyme. Functional bladder disorder [GC50] [75]
Mirabegron DMS1GYT Minor Increased metabolism of Rifabutin caused by Mirabegron mediated induction of CYP450 enzyme. Functional bladder disorder [GC50] [76]
Itraconazole DMCR1MV Major Increased metabolism of Rifabutin caused by Itraconazole mediated induction of CYP450 enzyme. Fungal infection [1F29-1F2F] [77]
Miconazole DMPMYE8 Minor Decreased metabolism of Rifabutin caused by Miconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [30]
Ketoconazole DMPZI3Q Major Increased metabolism of Rifabutin caused by Ketoconazole mediated induction of CYP450 enzyme. Fungal infection [1F29-1F2F] [77]
Ripretinib DM958QB Major Increased metabolism of Rifabutin caused by Ripretinib mediated induction of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [78]
Sunitinib DMCBJSR Moderate Increased metabolism of Rifabutin caused by Sunitinib mediated induction of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [37]
Avapritinib DMK2GZX Major Increased metabolism of Rifabutin caused by Avapritinib mediated induction of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [30]
Digitoxin DMWVIGP Moderate Increased metabolism of Rifabutin caused by Digitoxin mediated induction of CYP450 enzyme. Heart failure [BD10-BD1Z] [79]
Boceprevir DMBSHMF Major Decreased metabolism of Rifabutin caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [80]
PSI-7977 DMLSUWZ Major Accelerated clearance of Rifabutin due to the transporter induction by PSI-7977. Hepatitis virus infection [1E50-1E51] [30]
Simeprevir DMLUA9D Major Increased metabolism of Rifabutin caused by Simeprevir mediated induction of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [81]
Telaprevir DMMRV29 Major Increased metabolism of Rifabutin caused by Telaprevir mediated induction of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [80]
Daclatasvir DMSFK9V Major Increased metabolism of Rifabutin caused by Daclatasvir mediated induction of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [30]
Isoniazid DM5JVS3 Minor Increased risk of hepatotoxicity by the combination of Rifabutin and Isoniazid. HIV-infected patients with tuberculosis [1B10-1B14] [77]
Rifapentine DMCHV4I Moderate Increased metabolism of Rifabutin caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [82]
Pretomanid DMDYA31 Major Increased metabolism of Rifabutin caused by Pretomanid mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [83]
MK-1439 DM215WE Major Increased metabolism of Rifabutin caused by MK-1439 mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [84]
Delavirdine DM3NF5G Major Increased metabolism of Rifabutin caused by Delavirdine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [85]
Fosamprenavir DM4W9B3 Moderate Decreased metabolism of Rifabutin caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [86]
Fostemsavir DM50ILT Minor Increased metabolism of Rifabutin caused by Fostemsavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [87]
Cobicistat DM6L4H2 Major Decreased metabolism of Rifabutin caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [30]
Tipranavir DM8HJX6 Moderate Decreased metabolism of Rifabutin caused by Tipranavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [88]
Efavirenz DMC0GSJ Moderate Increased metabolism of Rifabutin caused by Efavirenz mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [89]
Dolutegravir DMCZGRE Minor Increased metabolism of Rifabutin caused by Dolutegravir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [90]
Saquinavir DMG814N Moderate Increased metabolism of Rifabutin caused by Saquinavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [86]
Elvitegravir DMG9B1U Major Increased metabolism of Rifabutin caused by Elvitegravir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [37]
Etravirine DMGV8QU Major Increased metabolism of Rifabutin caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [91]
Rilpivirine DMJ0QOW Major Increased metabolism of Rifabutin caused by Rilpivirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [92]
Amprenavir DMLMXE0 Moderate Decreased metabolism of Rifabutin caused by Amprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [86]
Darunavir DMN3GCH Moderate Decreased metabolism of Rifabutin caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [86]
Atazanavir DMSYRBX Moderate Decreased metabolism of Rifabutin caused by Atazanavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [37]
Maraviroc DMTL94F Moderate Accelerated clearance of Rifabutin due to the transporter induction by Maraviroc. Human immunodeficiency virus disease [1C60-1C62] [37]
Raltegravir DMYURI6 Minor Increased metabolism of Rifabutin caused by Raltegravir mediated induction of UGT. Human immunodeficiency virus disease [1C60-1C62] [25]
Clofibrate DMPC1J7 Minor Increased metabolism of Rifabutin caused by Clofibrate mediated induction of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [93]
Paricalcitol DMYBV3G Moderate Increased metabolism of Rifabutin caused by Paricalcitol mediated induction of CYP450 enzyme. Hyper-parathyroidism [5A51] [49]
Levamlodipine DM92S6N Major Increased metabolism of Rifabutin caused by Levamlodipine mediated induction of CYP450 enzyme. Hypertension [BA00-BA04] [28]
Verapamil DMA7PEW Moderate Increased metabolism of Rifabutin caused by Verapamil mediated induction of CYP450 enzyme. Hypertension [BA00-BA04] [94]
Felodipine DMOSW35 Major Increased metabolism of Rifabutin caused by Felodipine mediated induction of CYP450 enzyme. Hypertension [BA00-BA04] [28]
Tolvaptan DMIWFRL Major Increased metabolism of Rifabutin caused by Tolvaptan mediated induction of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [30]
Fludrocortisone DMUDIR8 Moderate Increased metabolism of Rifabutin caused by Fludrocortisone mediated induction of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [95]
Suvorexant DM0E6S3 Moderate Increased metabolism of Rifabutin caused by Suvorexant mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [96]
Ramelteon DM7IW9J Moderate Increased metabolism of Rifabutin caused by Ramelteon mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [97]
Flurazepam DMAL4G0 Minor Increased metabolism of Rifabutin caused by Flurazepam mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [31]
Triazolam DMETYK5 Minor Increased metabolism of Rifabutin caused by Triazolam mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [31]
Zaleplon DMGFWSM Minor Increased metabolism of Rifabutin caused by Zaleplon mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [98]
Tasimelteon DMLOQ1V Major Increased metabolism of Rifabutin caused by Tasimelteon mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [99]
ITI-007 DMUQ1DO Major Increased metabolism of Rifabutin caused by ITI-007 mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [100]
Quazepam DMY4D87 Minor Increased metabolism of Rifabutin caused by Quazepam mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [31]
Estazolam DMZGXUM Minor Increased metabolism of Rifabutin caused by Estazolam mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [31]
Naloxegol DML0B41 Moderate Increased metabolism of Rifabutin caused by Naloxegol mediated induction of CYP450 enzyme. Large intestine motility disorder [DB32] [101]
Pemigatinib DM819JF Major Increased metabolism of Rifabutin caused by Pemigatinib mediated induction of CYP450 enzyme. Liver cancer [2C12] [30]
Crizotinib DM4F29C Major Increased metabolism of Rifabutin caused by Crizotinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [37]
Brigatinib DM7W94S Major Increased metabolism of Rifabutin caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [37]
Ceritinib DMB920Z Moderate Increased metabolism of Rifabutin caused by Ceritinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [102]
Lurbinectedin DMEFRTZ Major Decreased metabolism of Rifabutin caused by Lurbinectedin mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [103]
PF-06463922 DMKM7EW Major Increased metabolism of Rifabutin caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [104]
Osimertinib DMRJLAT Major Increased metabolism of Rifabutin caused by Osimertinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [37]
BIBW 2992 DMTKD7Q Moderate Accelerated clearance of Rifabutin due to the transporter induction by BIBW 2992. Lung cancer [2C25] [105]
Pralsetinib DMWU0I2 Major Increased metabolism of Rifabutin caused by Pralsetinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [106]
Capmatinib DMYCXKL Major Increased metabolism of Rifabutin caused by Capmatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [107]
Selpercatinib DMZR15V Major Increased metabolism of Rifabutin caused by Selpercatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [30]
Hydroxychloroquine DMSIVND Moderate Increased metabolism of Rifabutin caused by Hydroxychloroquine mediated induction of CYP450 enzyme. Malaria [1F40-1F45] [37]
Idelalisib DM602WT Moderate Increased metabolism of Rifabutin caused by Idelalisib mediated induction of CYP450 enzyme. Mature B-cell leukaemia [2A82] [108]
GDC-0199 DMH0QKA Major Increased metabolism of Rifabutin caused by GDC-0199 mediated induction of CYP450 enzyme. Mature B-cell leukaemia [2A82] [109]
IPI-145 DMWA24P Moderate Increased metabolism of Rifabutin caused by IPI-145 mediated induction of CYP450 enzyme. Mature B-cell leukaemia [2A82] [110]
Acalabrutinib DM7GCVW Moderate Increased metabolism of Rifabutin caused by Acalabrutinib mediated induction of CYP450 enzyme. Mature B-cell lymphoma [2A85] [111]
Ibrutinib DMHZCPO Major Increased metabolism of Rifabutin caused by Ibrutinib mediated induction of CYP450 enzyme. Mature B-cell lymphoma [2A85] [30]
Ponatinib DMYGJQO Moderate Increased metabolism of Rifabutin caused by Ponatinib mediated induction of CYP450 enzyme. Mature B-cell lymphoma [2A85] [37]
Vemurafenib DM62UG5 Major Increased metabolism of Rifabutin caused by Vemurafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [37]
Selumetinib DMC7W6R Major Increased metabolism of Rifabutin caused by Selumetinib mediated induction of CYP450 enzyme. Melanoma [2C30] [112]
LGX818 DMNQXV8 Major Increased metabolism of Rifabutin caused by LGX818 mediated induction of CYP450 enzyme. Melanoma [2C30] [113]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Rifabutin caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [37]
Estrone DM5T6US Moderate Increased metabolism of Rifabutin caused by Estrone mediated induction of CYP450 enzyme. Menopausal disorder [GA30] [40]
Ethinyl estradiol DMODJ40 Major Increased metabolism of Rifabutin caused by Ethinyl estradiol mediated induction of CYP450 enzyme. Menopausal disorder [GA30] [56]
Rimegepant DMHOAUG Major Increased metabolism of Rifabutin caused by Rimegepant mediated induction of CYP450 enzyme. Migraine [8A80] [114]
Exjade DMHPRWG Moderate Decreased metabolism of Rifabutin caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [115]
Dihydrotachysterol DMFB97P Moderate Increased metabolism of Rifabutin caused by Dihydrotachysterol mediated induction of CYP450 enzyme. Mineral deficiency [5B5K] [49]
Flibanserin DM70DTN Major Increased metabolism of Rifabutin caused by Flibanserin mediated induction of CYP450 enzyme. Mood disorder [6A60-6E23] [116]
Midazolam DMXOELT Minor Increased metabolism of Rifabutin caused by Midazolam mediated induction of CYP450 enzyme. Mood/affect symptom [MB24] [31]
Panobinostat DM58WKG Major Increased metabolism of Rifabutin caused by Panobinostat mediated induction of CYP450 enzyme. Multiple myeloma [2A83] [117]
Siponimod DM2R86O Major Increased metabolism of Rifabutin caused by Siponimod mediated induction of CYP450 enzyme. Multiple sclerosis [8A40] [37]
Deflazacort DMV0RNS Major Increased metabolism of Rifabutin caused by Deflazacort mediated induction of CYP450 enzyme. Muscular dystrophy [8C70] [30]
Romidepsin DMT5GNL Moderate Increased metabolism of Rifabutin caused by Romidepsin mediated induction of CYP450 enzyme. Mycosis fungoides [2B01] [118]
Fedratinib DM4ZBK6 Major Increased metabolism of Rifabutin caused by Fedratinib mediated induction of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [30]
Nilotinib DM7HXWT Major Increased metabolism of Rifabutin caused by Nilotinib mediated induction of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [119]
Ruxolitinib DM7Q98D Moderate Increased metabolism of Rifabutin caused by Ruxolitinib mediated induction of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [120]
Imatinib DM7RJXL Major Increased metabolism of Rifabutin caused by Imatinib mediated induction of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [121]
Dasatinib DMJV2EK Major Increased metabolism of Rifabutin caused by Dasatinib mediated induction of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [37]
Rolapitant DM8XP26 Major Increased metabolism of Rifabutin caused by Rolapitant mediated induction of CYP450 enzyme. Nausea/vomiting [MD90] [30]
Netupitant DMEKAYI Major Increased metabolism of Rifabutin caused by Netupitant mediated induction of CYP450 enzyme. Nausea/vomiting [MD90] [37]
Dolasetron DMMG26Z Minor Increased metabolism of Rifabutin caused by Dolasetron mediated induction of CYP450 enzyme. Nausea/vomiting [MD90] [122]
Ondansetron DMOTQ1I Moderate Increased metabolism of Rifabutin caused by Ondansetron mediated induction of CYP450 enzyme. Nausea/vomiting [MD90] [123]
E-2007 DMJDYNQ Moderate Increased metabolism of Rifabutin caused by E-2007 mediated induction of CYP450 enzyme. Neuropathy [8C0Z] [30]
Entrectinib DMMPTLH Major Increased metabolism of Rifabutin caused by Entrectinib mediated induction of CYP450 enzyme. Non-small cell lung cancer [2C25] [124]
Levomethadyl Acetate DM06HG5 Major Increased metabolism of Rifabutin caused by Levomethadyl Acetate mediated induction of CYP450 enzyme. Opioid use disorder [6C43] [125]
S-297995 DM26IH8 Moderate Increased metabolism of Rifabutin caused by S-297995 mediated induction of CYP450 enzyme. Opioid use disorder [6C43] [30]
Olaparib DM8QB1D Major Increased metabolism of Rifabutin caused by Olaparib mediated induction of CYP450 enzyme. Ovarian cancer [2C73] [37]
Rucaparib DM9PVX8 Moderate Increased metabolism of Rifabutin caused by Rucaparib mediated induction of CYP450 enzyme. Ovarian cancer [2C73] [126]
Buprenorphine DMPRI8G Moderate Increased metabolism of Rifabutin caused by Buprenorphine mediated induction of CYP450 enzyme. Pain [MG30-MG3Z] [127]
Hydrocodone DMQ2JO5 Major Increased metabolism of Rifabutin caused by Hydrocodone mediated induction of CYP450 enzyme. Pain [MG30-MG3Z] [25]
Istradefylline DM20VSK Major Increased metabolism of Rifabutin caused by Istradefylline mediated induction of CYP450 enzyme. Parkinsonism [8A00] [128]
Pimavanserin DMR7IVC Moderate Increased metabolism of Rifabutin caused by Pimavanserin mediated induction of CYP450 enzyme. Parkinsonism [8A00] [129]
Abametapir DM2RX0I Moderate Decreased metabolism of Rifabutin caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [130]
Macimorelin DMQYJIR Moderate Increased metabolism of Rifabutin caused by Macimorelin mediated induction of CYP450 enzyme. Pituitary gland disorder [5A60-5A61] [131]
Lefamulin DME6G97 Major Accelerated clearance of Rifabutin due to the transporter induction by Lefamulin. Pneumonia [CA40] [132]
Prednisone DM2HG4X Moderate Increased metabolism of Rifabutin caused by Prednisone mediated induction of CYP450 enzyme. Postoperative inflammation [1A00-CA43] [95]
Hydrocortisone DMGEMB7 Moderate Increased metabolism of Rifabutin caused by Hydrocortisone mediated induction of CYP450 enzyme. Postoperative inflammation [1A00-CA43] [95]
Ergonovine DM0VEC1 Moderate Increased metabolism of Rifabutin caused by Ergonovine mediated induction of CYP450 enzyme. Postpartum haemorrhage [JA43] [37]
Lonafarnib DMGM2Z6 Major Increased metabolism of Rifabutin caused by Lonafarnib mediated induction of CYP450 enzyme. Premature ageing appearance [LD2B] [133]
ABIRATERONE DM8V75C Major Increased metabolism of Rifabutin caused by ABIRATERONE mediated induction of CYP450 enzyme. Prostate cancer [2C82] [134]
Enzalutamide DMGL19D Moderate Increased metabolism of Rifabutin caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [135]
Darolutamide DMV7YFT Moderate Increased metabolism of Rifabutin caused by Darolutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [136]
Silodosin DMJSBT6 Moderate Increased metabolism of Rifabutin caused by Silodosin mediated induction of CYP450 enzyme. Prostate hyperplasia [GA90] [37]
Apremilast DMTWS9E Moderate Increased metabolism of Rifabutin caused by Apremilast mediated induction of CYP450 enzyme. Psoriasis [EA90] [137]
Riociguat DMXBLMP Moderate Increased metabolism of Rifabutin caused by Riociguat mediated induction of CYP450 enzyme. Pulmonary hypertension [BB01] [138]
Temsirolimus DMS104F Major Increased metabolism of Rifabutin caused by Temsirolimus mediated induction of CYP450 enzyme. Renal cell carcinoma [2C90] [37]
Upadacitinib DM32B5U Moderate Increased metabolism of Rifabutin caused by Upadacitinib mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [139]
Dexamethasone DMMWZET Moderate Increased metabolism of Rifabutin caused by Dexamethasone mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [95]
Quetiapine DM1N62C Moderate Increased metabolism of Rifabutin caused by Quetiapine mediated induction of CYP450 enzyme. Schizophrenia [6A20] [37]
Aripiprazole DM3NUMH Moderate Increased metabolism of Rifabutin caused by Aripiprazole mediated induction of CYP450 enzyme. Schizophrenia [6A20] [140]
Fentanyl DM8WAHT Major Increased metabolism of Rifabutin caused by Fentanyl mediated induction of CYP450 enzyme. Sensation disturbance [MB40] [25]
Avanafil DM75CXN Moderate Increased metabolism of Rifabutin caused by Avanafil mediated induction of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [141]
Tadalafil DMJZHT1 Moderate Increased metabolism of Rifabutin caused by Tadalafil mediated induction of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [30]
Voxelotor DMCS6M5 Major Increased metabolism of Rifabutin caused by Voxelotor mediated induction of CYP450 enzyme. Sickle-cell disorder [3A51] [142]
LDE225 DMM9F25 Major Increased metabolism of Rifabutin caused by LDE225 mediated induction of CYP450 enzyme. Skin cancer [2C30-2C37] [143]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Rifabutin caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [30]
Larotrectinib DM26CQR Major Accelerated clearance of Rifabutin due to the transporter induction by Larotrectinib. Solid tumour/cancer [2A00-2F9Z] [37]
Methylprednisolone DM4BDON Moderate Increased metabolism of Rifabutin caused by Methylprednisolone mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [95]
Docetaxel DMDI269 Moderate Increased metabolism of Rifabutin caused by Docetaxel mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [144]
Trabectedin DMG3Y89 Moderate Increased metabolism of Rifabutin caused by Trabectedin mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [30]
Armodafinil DMGB035 Moderate Increased metabolism of Rifabutin caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [145]
LEE011 DMMX75K Major Increased metabolism of Rifabutin caused by LEE011 mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [146]
Prednisolone DMQ8FR2 Moderate Increased metabolism of Rifabutin caused by Prednisolone mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [95]
Vandetanib DMRICNP Moderate Increased metabolism of Rifabutin caused by Vandetanib mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [147]
Norethindrone DMTY169 Major Increased metabolism of Rifabutin caused by Norethindrone mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [56]
Taxol DMUOT9V Moderate Increased metabolism of Rifabutin caused by Taxol mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [148]
Doxorubicin DMVP5YE Moderate Increased metabolism of Rifabutin caused by Doxorubicin mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [30]
Pitolisant DM8RFNJ Major Increased metabolism of Rifabutin caused by Pitolisant mediated induction of CYP450 enzyme. Somnolence [MG42] [30]
Warfarin DMJYCVW Major Increased metabolism of Rifabutin caused by Warfarin mediated induction of CYP450 enzyme. Supraventricular tachyarrhythmia [BC81] [52]
Pomalidomide DMTGBAX Moderate Accelerated clearance of Rifabutin due to the transporter induction by Pomalidomide. Systemic sclerosis [4A42] [149]
Fostamatinib DM6AUHV Moderate Increased metabolism of Rifabutin caused by Fostamatinib mediated induction of CYP450 enzyme. Thrombocytopenia [3B64] [150]
As-1670542 DMV05SW Moderate Increased metabolism of Rifabutin caused by As-1670542 mediated induction of CYP450 enzyme. Thrombocytopenia [3B64] [30]
Apixaban DM89JLN Moderate Increased metabolism of Rifabutin caused by Apixaban mediated induction of CYP450 enzyme. Thrombosis [DB61-GB90] [151]
Brilinta DMBR01X Moderate Increased metabolism of Rifabutin caused by Brilinta mediated induction of CYP450 enzyme. Thrombosis [DB61-GB90] [25]
Cabozantinib DMIYDT4 Major Increased metabolism of Rifabutin caused by Cabozantinib mediated induction of CYP450 enzyme. Thyroid cancer [2D10] [152]
Sirolimus DMGW1ID Major Accelerated clearance of Rifabutin due to the transporter induction by Sirolimus. Transplant rejection [NE84] [37]
Tacrolimus DMZ7XNQ Major Increased metabolism of Rifabutin caused by Tacrolimus mediated induction of CYP450 enzyme. Transplant rejection [NE84] [153]
Tolbutamide DM02AWV Moderate Increased metabolism of Rifabutin caused by Tolbutamide mediated induction of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [22]
Saxagliptin DMGXENV Moderate Increased metabolism of Rifabutin caused by Saxagliptin mediated induction of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [154]
Chlorpropamide DMPHZQE Moderate Increased metabolism of Rifabutin caused by Chlorpropamide mediated induction of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [22]
Linagliptin DMWFJTR Moderate Increased metabolism of Rifabutin caused by Linagliptin mediated induction of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [155]
Elagolix DMB2C0E Moderate Accelerated clearance of Rifabutin due to the transporter induction by Elagolix. Uterine fibroid [2E86] [156]
Betrixaban DM2C4RF Moderate Accelerated clearance of Rifabutin due to the transporter induction by Betrixaban. Venous thromboembolism [BD72] [157]
Amiodarone DMUTEX3 Major Increased metabolism of Rifabutin caused by Amiodarone mediated induction of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [158]
⏷ Show the Full List of 234 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Crospovidone E00626 Not Available Disintegrant
Eisenoxyd E00585 56841934 Colorant
Magnesium stearate E00208 11177 lubricant
Potassium hydroxide E00233 14797 Alkalizing agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
⏷ Show the Full List of 7 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Rifabutin 150 mg capsule 150 mg Oral Capsule Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Novel agents in the management of Mycobacterium tuberculosis disease. Curr Med Chem. 2007;14(18):2000-8.
2 BDDCS applied to over 900 drugs
3 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
4 An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
5 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
8 The effect of multiple doses of ritonavir on the pharmacokinetics of rifabutin. Clin Pharmacol Ther. 1998 Apr;63(4):414-21.
9 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
10 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
11 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
12 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
13 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
14 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
15 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
16 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
17 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
18 Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 1998 Jul;42(7):1853-7.
19 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
20 Bernard A, Kermarrec G, Parize P, et.al "Dramatic reduction of clindamycin serum concentration in staphylococcal osteoarticular infection patients treated with the oral clindamycin-rifampicin combination." J Infect 71 (2015): 200-6. [PMID: 25936632]
21 Bidstrup TB, Bjornsdottir I, Sidelmann UG, Thomsen MS, Hansen KT "CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide." Br J Clin Pharmacol 56 (2003): 305-14. [PMID: 12919179]
22 Borcherding SM, Baciewicz AM, Self TH "Update on rifampin drug interactions." Arch Intern Med 152 (1992): 711-6. [PMID: 1558427]
23 Jaakkola T, Backman JT, Neuvonen M, Laitila J, Neuvonen PJ "Effect of rifampicin on the pharmacokinetics of pioglitazone." Br J Clin Pharmacol 61 (2006): 70-8. [PMID: 16390353]
24 Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y "Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers." Cancer Chemother Pharmacol 72 (2013): 1223-34. [PMID: 24085261]
25 Canadian Pharmacists Association.
26 Product Information. Aricept (donepezil). Pfizer US Pharmaceuticals, New York, NY.
27 Product Information. Tindamax (tinidazole). Presutti Laboratories Inc, Arlington Heights, IL.
28 Product Information. Mycobutin (rifabutin). Pharmacia and Upjohn, Kalamazoo, MI.
29 Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
30 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
31 Ochs HR, Greenblatt DJ, Roberts GM, Dengler HJ "Diazepam interaction with antituberculosis drugs." Clin Pharmacol Ther 29 (1981): 671-8. [PMID: 7214796]
32 Apseloff G, Foulds G, LaBoy-Goral L, Willavize S, Vincent J "Comparison of azithromycin and clarithromycin in their interactions with rifabutin in healthy volunteers." J Clin Pharmacol 38 (1998): 830-5. [PMID: 9753212]
33 Product Information. Vraylar (cariprazine). Actavis Pharma, Inc., Parsippany, NJ.
34 Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
35 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
36 Product Information. Ixempra (ixabepilone). Bristol-Myers Squibb, Princeton, NJ.
37 Cerner Multum, Inc. "Australian Product Information.".
38 Product Information. Verzenio (abemaciclib). Lilly, Eli and Company, Indianapolis, IN.
39 Product Information. Aromasin (exemestane) Pharmacia & Upjohn, Kalamazoo, MI.
40 Baciewicz AM "Oral contraceptive drug interactions." Ther Drug Monit 7 (1985): 26-35. [PMID: 2859674]
41 Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
42 Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
43 Biochem Pharmacol "Variable contribution of cytochromes P450 2D6, 2C9, and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes." Biochem Pharmacol 53 (1997): 171-8. [PMID: 9037249]
44 Product Information. Jevtana (cabazitaxel). sanofi-aventis , Bridgewater, NJ.
45 Product Information. Bosulif (bosutinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
46 Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH "Interindividual variation and drug interactions with hormonal steroid contraceptives." Drugs 21 (1981): 46-61. [PMID: 7009137]
47 Bullman J, Nicholls A, Van Landingham K, et al. "Effects of lamotrigine and phenytoin on the pharmacokinetics of atorvastatin in healthy volunteers." Epilepsia 52 (2011): 1351-8. [PMID: 21635243]
48 Bruderer S, Aanismaa P, Homery MC, et al. "Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist." AAPS J 14 (2012): 68-78. [PMID: 22189899]
49 Product Information. Hectorol (doxercalciferol). Genzyme Corporation, Cambridge, MA.
50 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
51 Caraco Y, Sheller J, Wood AJ "Pharmacogenetic determinants of codeine induction by rifampin: the impact on codeine's respiratory, psychomotor and miotic effects." J Pharmacol Exp Ther 281 (1997): 330-6. [PMID: 9103514]
52 Rifampin.?Tuberculosis (Edinb). 2008;88(2):151-154. doi:10.1016/S1472-9792(08)70024-6. [PMID: 18486058]
53 Product Information. Stivarga (regorafenib). Bayer Pharmaceutical Inc, West Haven, CT.
54 Crews KR, Stewart CF, Jones-Wallace D, et al "Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy." Clin Cancer Res 8 (2002): 2202-9. [PMID: 12114421]
55 Archer JS, Archer DF "Oral contraceptive efficacy and antibiotic interaction: A myth debunked." J Am Acad Dermatol 46 (2002): 917-23. [PMID: 12063491]
56 Back DJ, Breckenridge AM, Crawford F, et al. "The effect of rifampicin on norethisterone pharmacokinetics." Eur J Clin Pharmacol 15 (1979): 193-7. [PMID: 37091]
57 Product Information. Chirocaine (levobupivacaine) Organon, West Orange, NJ.
58 Bartelink AK, Lenders JW, van Herwaarden CL, et al "Fatal hepatitis after treatment with isoniazid and rifampicin in a patient on anticonvulsant therapy." Tubercle 64 (1983): 125-8. [PMID: 6612792]
59 Kharasch ED, Thummel KE "Human alfentanil metabolism by cytochrome P450 3A3/4. An explanation for the interindividual variability in alfentanil clearance?" Anesth Analg 76 (1993): 1033-9. [PMID: 8484504]
60 He K, Woolf TF, Hollenberg PF "Mechanism-based inactivation of cytochrome P-450-3A4 by mifepristone (RU486)." J Pharmacol Exp Ther 288 (1999): 791-7. [PMID: 9918590]
61 Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
62 Product Information. Viibryd (vilazodone). Trovis Pharmaceuticals LLC, New Haven, CT.
63 Product Information. Serzone (nefazodone). Bristol-Myers Squibb, Princeton, NJ.
64 Product Information. Brintellix (vortioxetine). Takeda Pharmaceuticals America, Lincolnshire, IL.
65 Product Information. Rexulti (brexpiprazole). Otsuka American Pharmaceuticals Inc, Rockville, MD.
66 Product Information. Osphena (ospemifene). Shionogi USA Inc, Florham Park, NJ.
67 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
68 Nakasa H, Nakamura H, Ono S, Tsutsui M, Kiuchi M, Ohmori S, Kitada M "Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data." Eur J Clin Pharmacol 54 (1998): 177-83. [PMID: 9626925]
69 Glue P, Banfield CR, Perhach JL, Mather GG, Racha JK, Levy RH "Pharmacokinetic interactions with felbamate.In vitro-in vivo correlation." Clin Pharmacokinet 33 (1997): 214-24. [PMID: 9314612]
70 Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
71 Abajo FJ "Phenytoin interaction with rifampicin." Br Med J 297 (1988): 1048. [PMID: 3142625]
72 Bittencourt PR, Gracia CM, Martins R, et al "Phenytoin and carbamazepine decrease oral bioavailability of praziquantel." Neurology 42 (1992): 492-6. [PMID: 1549207]
73 Product Information. Aliqopa (copanlisib). Bayer Pharmaceutical Inc, West Haven, CT.
74 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
75 Product Information. VESIcare (solifenacin). GlaxoSmithKline, Research Triangle Park, NC.
76 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
77 Abadie-Kemmerly S, Pankey GA, Dalvisio JR "Failure of ketoconazole treatment of blastomyces dermatidis due to interaction of isoniazid and rifampin." Ann Intern Med 109 (1988): 844-5. [PMID: 3190036]
78 Product Information. Qinlock (ripretinib). Deciphera Pharmaceuticals, Waltham, MA.
79 Boman G, Eliasson K, Odar-Cederlof I "Acute cardiac failure during treatment with digoxin--an interaction with rifampicin." Br J Clin Pharmacol 10 (1980): 89-90. [PMID: 7397060]
80 Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.
81 Product Information. Olysio (simeprevir). Janssen Pharmaceuticals, Titusville, NJ.
82 Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
83 Product Information. Pretomanid (pretomanid). The Global Alliance for TB Drug Development, New York, NY.
84 Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
85 Borin MT, Chambers JH, Carel BJ, Freimuth WW, Aksentijevich S, Piergies AA "Pharmacokinetic study of the interaction between rifabutin and delavirdine mesylate in HIV-1 infected patients." Antiviral Res 35 (1997): 53-63. [PMID: 9224961]
86 American Thoracic Society, CDC, Infectious Diseases Society of America "Treatment of tuberculosis." MMWR Morb Mortal Wkly Rep 52(RR-11) (2003): 1-77. [PMID: 12836625]
87 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
88 Product Information. Aptivus (tipranavir). Boehringer-Ingelheim, Ridgefield, CT.
89 Burman WJ, Jones BE "Treatment of HIV-related tuberculosis in the era of effective antiretroviral therapy." Am J Respir Crit Care Med 164 (2001): 7-12. [PMID: 11435232]
90 Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC.
91 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
92 Product Information. Edurant (rilpivirine). Tibotec Pharmaceuticals, Titusville, NJ.
93 Houin G, Tillement JP "Clofibrate and enzymatic induction in man." Int J Clin Pharmacol 16 (1978): 150-4. [PMID: 649234]
94 Barbarash RA "Verapamil-rifampin interaction." Drug Intell Clin Pharm 19 (1985): 559-60. [PMID: 4028962]
95 Bergrem H, Refvem OK "Altered prednisolone pharmacokinetics in patients treated with rifampicin." Acta Med Scand 213 (1983): 339-43. [PMID: 6880856]
96 Product Information. Belsomra (suvorexant). Merck & Company Inc, Whitehouse Station, NJ.
97 Product Information. Rozerem (ramelteon). Takeda Pharmaceuticals America, Lincolnshire, IL.
98 Product Information. Sonata (zaleplon) Wyeth-Ayerst Laboratories, Philadelphia, PA.
99 Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
100 Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY.
101 Product Information. Movantik (naloxegol). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
102 Product Information. Zykadia (ceritinib). Novartis Pharmaceuticals, East Hanover, NJ.
103 Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
104 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
105 Product Information. Gilotrif (afatinib). Boehringer Ingelheim, Ridgefield, CT.
106 Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA.
107 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
108 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
109 Product Information. Venclexta (venetoclax). AbbVie US LLC, North Chicago, IL.
110 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
111 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
112 Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
113 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
114 Product Information. Nurtec ODT (rimegepant). Biohaven Pharmaceuticals, New Haven, CT.
115 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
116 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
117 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
118 Product Information. Istodax (romidepsin). Gloucester Pharmaceuticals, Cambridge, MA.
119 Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
120 Product Information. Jakafi (ruxolitinib). Incyte Corporation, Wilmington, DE.
121 Bolton AE, Peng B, Hubert M, et al. "Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects." Cancer Chemother Pharmacol 53 (2004): 102-6. [PMID: 14605865]
122 Product Information. Anzemet (dolasetron). Hoechst Marion-Roussel Inc, Kansas City, MO.
123 Villikka K, Kivisto KT, Neuvonen PJ "The effect of rifampin on the pharmacokinetics of oral and intravenous ondansetron." Clin Pharmacol Ther 65 (1999): 377-81. [PMID: 10223773]
124 Product Information. Rozlytrek (entrectinib). Genentech, South San Francisco, CA.
125 Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John's Wort." Am J Med 112 (2002): 507-8. [PMID: 11959071]
126 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
127 Product Information. Buprenex (buprenorphine). Reckitt and Colman Pharmaceutical, Richmond, VA.
128 Product Information. Nourianz (istradefylline). Kyowa Kirin, Inc, Bedminster, NJ.
129 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
130 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
131 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
132 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
133 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
134 Product Information. Zytiga (abiraterone). Centocor Inc, Malvern, PA.
135 Product Information. Xtandi (enzalutamide). Astellas Pharma US, Inc, Deerfield, IL.
136 Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
137 Product Information. Otezla (apremilast). Celgene Corporation, Summit, NJ.
138 Product Information. Adempas (riociguat). Bayer Pharmaceutical Inc, West Haven, CT.
139 Product Information. Rinvoq (upadacitinib). AbbVie US LLC, North Chicago, IL.
140 Product Information. Abilify (aripiprazole). Bristol-Myers Squibb, Princeton, NJ.
141 Product Information. Stendra (avanafil). Vivus Inc, Mountain View, CA.
142 Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
143 Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
144 Aronson JK, Grahame-Smith DG "Clinical pharmacology: adverse drug interactions." Br Med J 282 (1981): 288-91. [PMID: 6779990]
145 Product Information. Nuvigil (armodafinil). Cephalon Inc, West Chester, PA.
146 Product Information. Kisqali (ribociclib). Novartis Pharmaceuticals, East Hanover, NJ.
147 Martin P, Oliver S, Robertson J, Kennedy SJ, Read J, Duvauchelle T "Pharmacokinetic drug interactions with vandetanib during cadministration with rifampicin or itraconazole." Drugs R D 11 (2011): 37-51. [PMID: 21410294]
148 Jamis-Dow CA, Klecker RW, Katki AG, Collins JM "Metabolism of Taxol by human liver microsomes and effect of inhibitors (Meeting abstract)." Proc Annu Meet Am Assoc Cancer Res 34 (1993): a21981993.
149 Product Information. Pomalyst (pomalidomide). QLT Phototherapeutics Inc, Vancouver, AZ.
150 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
151 Product Information. Eliquis (apixaban). Bristol-Myers Squibb Canada Inc, Montreal, IN.
152 Product Information. Cabometyx (cabozantinib). Exelixis Inc, S San Francisco, CA.
153 Bhaloo S, Prasad GV "Severe reduction in tacrolimus levels with rifampin despite multiple cytochrome P450 inhibitors: a case report." Transplant Proc 35 (2003): 2449-51. [PMID: 14611983]
154 Product Information. Onglyza (saxagliptin). Bristol-Myers Squibb, Princeton, NJ.
155 Product Information. Tradjenta (linagliptin). Boehringer Ingelheim, Ridgefield, CT.
156 Product Information. Orilissa (elagolix). AbbVie US LLC, North Chicago, IL.
157 Gelosa P, Castiglioni L, Tenconi M, et.al "Pharmacokinetic drug interactions of the non-vitamin K antagonist oral anticoagulants (NOACs)" Pharmacol Res 135 (2018): 60-79. [PMID: 30040996]
158 Product Information. Cordarone (amiodarone). Wyeth-Ayerst Laboratories, Philadelphia, PA.